⌕

CVS Health (CVS) vs Elevance Health (ELV)

Your goal
● Balanced style: every factor counts equally.
#1 FIT · LEADS
63
Elevance Health Inc
$429.69 · $93B
Calmest ride
of the stocks compared here

The front-runner. Leads the balanced score. Its widest win over the field is balance sheet.

#2 FIT
61
CVS Health Corp
$89.35 · $114B
Highest qualityBest incomeCheapest
of the stocks compared here

The challenger. Trails the leader on the balanced score. Its widest win over the field is profitability & quality.

ELV barely leads (63/100 vs CVS 61) under a balanced style, mostly on balance sheet. But CVS wins on profitability & quality, so the comparison turns on what you weight. Switch your goal above and watch the scores move.

THE SCORECARD · FACTOR BY FACTOR · the best value in each row is ticked, and a tie ticks every tied column · weight bar shows how much it counts for your goal

FactorCVSELV
Overall fit score
weighted for your balanced goal
61
✓ 63
Valuation
Cheaper for what you get
1×
✓ P/E 10 · EV/EBITDA 18.2
P/E trailing
83
P/E 18 · EV/EBITDA 9.2
P/E trailing
80
Growth
Revenue & earnings momentum
1×
—
30
✓ —
40
Profitability & quality
Margins & return on capital
1×
✓ Net 3% · ROIC 10%
TTM through Sep 30, 2026
61
Net 3% · ROIC 8%
TTM through Sep 30, 2026
53
Total return
Share-price change with dividends reinvested
1×
✓ 5Y +2%/yr
58
5Y +1%/yr
57
Risk (calm = better)
Volatility & drawdown
1×
β 0.4 · DD −57%
88
✓ β 0.4 · DD −50%
91
Balance sheet†
Debt vs cash cushion
1×
Net debt/EBITDA 5.8×
fiscal 2025
11
✓ Net debt/EBITDA −0.4×
fiscal 2025
37
Dividend & income
Cash paid to you
1×
✓ 2.98% yield· B
97
1.59% yield· A+
90
Analyst sentiment
Forward EPS growth (consensus)
1×
✓ Est EPS +5%/yr · 15 analysts
58
Est EPS +4%/yr · 13 analysts
56
† Balance sheet is scored on 5 peer percentiles (current ratio, quick ratio, net debt/EBITDA, interest coverage and debt/equity). The cell shows one of them, so a column can lead on the printed number and still lose the row.
The letter beside the dividend yield is our dividend-safety grade (A+ to F), a read on how likely that dividend is to be cut. It does not grade the yield.
Loading chart…
WHERE EACH ONE IS STRONG
GrowthValueQualityReturnSafetyIncome
■ CVS■ ELV
CAN YOU STOMACH THE RIDE?
Worst drawdownBeta (vs market)VolatilityHistory
CVS−57%0.3931%5Y
ELV−50%0.3729%5Y
THE CASE FOR & AGAINST EACH
BULL CASE

▲ Leads on profitability & quality: Net 3% · ROIC 10% (score 61).

▲ Leads on dividend & income: 2.98% yield (score 97).

BEAR CASE

▼ Weakest on balance sheet (score 11). Net debt/EBITDA 5.8× is one of the 5 inputs.

▼ Weakest on growth: — (score 30).

BULL CASE

▲ Leads on risk (calm = better): β 0.4 · DD −50% (score 91).

BEAR CASE

▼ Weakest on profitability & quality: Net 3% · ROIC 8% (score 53).

▼ Weakest on dividend & income: 1.59% yield (score 90).

WHAT COULD CHANGE THE SCORE
Balance sheetCurrently 11/100 (Net debt/EBITDA 5.8×). Taking it to 100 would lift the balanced score by 11 points, the biggest single move available.
GrowthCurrently 30/100 (—). Taking it to 100 would lift the balanced score by 9 points, the next biggest.
Balance sheetCurrently 37/100 (Net debt/EBITDA −0.4×). Taking it to 100 would lift the balanced score by 8 points, the biggest single move available.
GrowthCurrently 40/100 (—). Taking it to 100 would lift the balanced score by 8 points, the next biggest.
Scores are Tenet composites, 0–100, reweighted for your selected goal. Seven of the eight factors are sector percentiles; analyst sentiment is an absolute curve on forward EPS growth, capped at 100, so two very high-growth names can share the top score. Moat/durability is not scored (qualitative, not measurable). Comparison is decision-support, not a recommendation · past performance does not predict future returns · Not investment advice · prices are each company's own latest close, the newest here being Nov 13, 2026 · valuation, growth, quality and balance scores from the Nov 16, 2026 scoring run · analyst consensus, return, risk and income scores computed Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.